A newly developed humanized anti-IL-26 monoclonal antibody effectively reduced T cell/neutrophil infiltration and fibroproliferation, demonstrating therapeutic potential for chronic GVHD treatment [40]. The gene discussed is IL26; the disease is chronic graft versus host disease.